Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 11/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 6/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046560 | 0.91 | SLC2A1 (0.50) | SLC2A1MEN1KMT2ASLC2A2 | |
| SCHEMBL4669868 | 0.84 | MC4R (0.45) | SLC2A1 | |
| SCHEMBL11934195 | 0.82 | SLC2A1 (0.42) | SLC2A1 | |
| SCHEMBL11929569 | 0.82 | SLC2A1 (0.43) | SLC2A1KCNK3KCNK9SLC2A2 | |
| SCHEMBL11929568 | 0.81 | SLC2A1 (0.41) | SLC2A1 | |
| SCHEMBL11929567 | 0.81 | SLC2A1 (0.44) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL4671674 | 0.81 | SLC2A1 (0.41) | SLC2A1 | |
| SCHEMBL12819374 | 0.81 | SLC2A1 (0.59) | SLC2A1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL4671342 | 0.81 | SLC2A1 (0.41) | SLC2A1 | |
| SCHEMBL12819331 | 0.80 | SLC2A1 (0.64) | SLC2A1KCNK3KCNK9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-1974729-A1 | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | MC4R, MC3R, MC5R | SLC2A1 3850/4885KCNK3 2573/4885KCNK9 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.